Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

SINOVAC Biotech Ltd. Announces Use of CoronaVac, its COVID-19 Vaccine on Child Population in China

07/20/2021 | 09:12am EDT

SINOVAC Biotech Ltd. announced CoronaVac, SINOVAC’s COVID-19 vaccine, has started being used among the child population in China. A study on immune persistency was conducted in 180 volunteers in a phase II clinical study on a group of participants ranging from 3 to 17 years of age. The results showed that, three months after two doses of the vaccine, the seroconversion rates for children and adolescents were 98.9% and 100%, respectively. The geometric mean titer (GMT) of neutralizing antibody was close to the level recorded at 28 days after vaccination and remained significantly higher than the level recorded in adults and elderly at 28 days after vaccination. This indicates that CoronaVac has stable and good immunogenicity among the pediatric and adolescent population, recording better results compared to those in people aged 18 and above. CoronaVac was approved for emergency use on May 28, 2021 in China. SINOVAC’s COVID-19 vaccine had also been filed for use in Indonesia and was approved for use in the population of 12 to 17 years of age by Indonesian authorities in June 2021. The Lancet Infectious Diseases has published results from the Phase I/II clinical trials of an inactivated COVID-19 vaccine developed by SINOVAC, also known as CoronaVac®, in healthy children aged 3 to 17 years of age in China.


© S&P Capital IQ 2021
All news about SINOVAC BIOTECH LTD.
09/24CANSINO BIOLOGICS : CanSinoBIO's COVID vaccine, tested at lower dosage, safe for children ..
RE
09/22SINOVAC BIOTECH : Thailand delays plan to re-open cities to tourists until November
RE
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/09SINOVAC BIOTECH : Says its New Research Shows Third Dose if its COVID-19 Vaccine More Effe..
MT
09/09SINOVAC BIOTECH : New Research on SINOVAC's COVID-19 Vaccine Shows Third Dose More Effecti..
BU
09/08SINOVAC BIOTECH : Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Child..
BU
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger response than Si..
RE
09/01SINOVAC BIOTECH : North Korea turns down Sinovac COVID-19 vaccine doses - WSJ
RE
08/24SINOVAC BIOTECH : COVID-19 booster shots should follow after China inoculates more -state ..
RE
08/23São Paulo City Will Require Proof of Vaccination to Enter Shops, Bars
DJ
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 33,5%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED8.15%101 656
WUXI BIOLOGICS (CAYMAN) INC.18.58%66 404
SAMSUNG BIOLOGICS CO.,LTD.11.38%51 643
BIOGEN INC.17.05%42 716
ALEXION PHARMACEUTICALS, INC.0.00%40 336